Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden’s Orexo Forms Partnership With Shanghai’s NovaMed To Enter Chinese Oncology Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Swedish pharmaceutical firm Orexo has signed an agreement with Shanghai-based NovaMed for the distribution of Orexo's cancer pain treatment Abstral (fast-dissolving fentanyl) in China

You may also be interested in...



Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline

SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)

Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline

SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)

NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News

Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.

Latest News
UsernamePublicRestriction

Register

SC070952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel